A Cell Press partner journal
 
Related commentsú║
 
Add comment (English only)
Name*:
E-mail:
Telephone:
Code:  
Comments*:
 Position: Home > issue > The 2nd Issue  
Patients' attitudes about access to unproven therapies in treating COVID-19 merit evaluation
Category: Commentary
Author: Hongtian Li

Percentages may not add up to 100% due to rounding.jpg

Patientsí» attitudes to unproven therapies in treating Covid-19 merit evaluation


Since the outbreak of Covid-19, many randomized controlled trials have been launched to test the efficacy of promising treatments. These trials will offer great promise for future treatment. However, a public health emergency calls for a balance between gathering sound evidence and granting therapeutic access to promising trial drugs as widely as possible. In an electronic survey we found that 3.9% of the participants preferred to receive an unproven trial drug directly in the hypothetical scenario of mild Covid-19 infection. This percentage increased drastically to 31.1% and 54.2% in the hypothetical scenario of severe and extremely severe infection, respectively. Our survey indicates a likelihood of substantial receptivity of trial drug among actual patients in severe conditions. From the perspective of deontological ethics, a trial can only be approved when potential benefits of the investigational treatment are presumed to outweigh risks, so compassionate or off-label use of investigational therapies merits evaluation.





[Printing]  [Close
Host:   Academic co-partner: Stay connected:
    SHANGHAI INSTITUTE OF APPLIED PHYSICS, CAS

  inquiry@the-innovation.org
  the.innovation.journal
  the.innovation.journal
  The_InnovationJ
  The Innovation┤┤đ┬
  The Innovation┤┤đ┬

Publishing partner:   INSTITUTE OF MICROBIOLOGY, CAS
  XI'AN INSTITUTE OF OPTICS AND PRECISION MECHANICS, CAS
  Copyright © 2019-2020 the-innovation.org All Rights Reserved